Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 14,040 Shares of Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 14,040 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $13.93, for a total transaction of $195,577.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Kenneth Hoberman also recently made the following trade(s):

  • On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total transaction of $169,351.74.
  • On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total transaction of $169,918.94.

Shares of Stemline Therapeutics Inc (NASDAQ:STML) traded up $0.25 during trading hours on Friday, reaching $14.10. 100,595 shares of the company were exchanged, compared to its average volume of 217,680. The stock has a market cap of $356.55, a PE ratio of -5.49 and a beta of -0.02. Stemline Therapeutics Inc has a one year low of $5.50 and a one year high of $16.20.

Several research firms have recently weighed in on STML. BidaskClub cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. Finally, Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $33.75.

A number of large investors have recently modified their holdings of STML. Voya Investment Management LLC purchased a new position in Stemline Therapeutics in the 2nd quarter worth $102,000. Nationwide Fund Advisors raised its position in Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 855 shares during the period. State of Wisconsin Investment Board purchased a new position in Stemline Therapeutics in the 2nd quarter worth $147,000. Alliancebernstein L.P. purchased a new position in Stemline Therapeutics in the 2nd quarter worth $178,000. Finally, The Manufacturers Life Insurance Company raised its position in Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 5,522 shares during the period. Institutional investors own 50.24% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/stemline-therapeutics-inc-stml-coo-kenneth-hoberman-sells-14040-shares-of-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply